Avalo Therapeutics, Inc.（AVTX）の株式分析AVTXAvalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Avalo Therapeutics Inc is currently not a good buy due to its significant price decline and negative financial performance, despite some positive analyst outlooks. The current price is $6.93, which is down 61.48% over the past year, and the RSI is extremely low at 11.716, indicating oversold conditions. The main risk is the negative earnings per share of -0.83 reported last quarter, which reflects ongoing financial struggles.